The trajectory of Sildenafil presents a challenging picture for investors. While the initial launch generated massive gains, the end of its patent opened the door to cheaper versions, dramatically eroding revenue. This https://sahilxazb551201.blogoscience.com/48547427/the-copyright-and-big-pharma-a-volatile-opportunity